Payment overview · 2025
General Payments
$2,652.19
93 reported records · 17 companies
Healthcare provider profile · identity verified
Tom Ku, P.A.-C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical · CORONA, CA · NPI 1609955285
Verified facts
What the public records show
CMS Open Payments records show Tom Ku, P.A.-C received $2,652.19 in general payments during 2025 across 93 reported records.
AstraZeneca Pharmaceuticals LP accounted for 27.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Jardiance, Linzess, Mounjaro, Nurtec Odt, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $716.12 | 27.0% | 13 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $491.67 | 18.5% | 21 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $462.11 | 17.4% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $284.60 | 10.7% | 11 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $205.37 | 7.7% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $186.56 | 7.0% | 22 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $42.98 | 1.6% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $37.44 | 1.4% | 2 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $36.90 | 1.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $33.04 | 1.2% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $30.00 | 1.1% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $26.09 | 1.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.99 | 0.9% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $23.73 | 0.9% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.47 | 0.8% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.65 | 0.6% | 1 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $13.47 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,652.19 | 93 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $543.78 | 9 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $491.67 | 21 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $344.66 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $265.84 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $252.15 | 19 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $238.67 | 8 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $205.37 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $200.24 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $176.25 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $113.67 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $108.41 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $105.85 | 7 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $56.24 | 13 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $51.54 | 12 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $42.98 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $41.02 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $37.44 | 2 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $36.90 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $30.00 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $26.09 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.99 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $23.73 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.04 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $21.47 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $17.61 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.65 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $13.47 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $13.47 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $13.47 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $4.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 107 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 58 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 44 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 82 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 107 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
58 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
107 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
44 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
77 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
82 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
107 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 652 | 167 |
| Gabapentin | Gabapentin | 477 | 115 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 347 | 55 |
| Levothyroxine Sodium | Levothyroxine Sodium | 320 | 82 |
| Amlodipine Besylate | Amlodipine Besylate | 296 | 78 |
| Pantoprazole Sodium | Pantoprazole Sodium | 289 | 67 |
| Losartan Potassium | Losartan Potassium | 273 | 75 |
| Lisinopril | Lisinopril | 254 | 74 |
| Lorazepam | Lorazepam | 208 | 32 |
| Metformin Hcl | Metformin Hcl | 207 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 205 | 55 |
| Alprazolam | Alprazolam | 204 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 204 | 67 |
| Omeprazole | Omeprazole | 203 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 201 | 55 |
| Metformin Hcl Er | Metformin Hcl | 184 | 45 |
| Furosemide | Furosemide | 180 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 179 | 53 |
| Meloxicam | Meloxicam | 161 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 149 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 148 | 36 |
| Baclofen | Baclofen | 140 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 127 | 33 |
| Tramadol Hcl | Tramadol Hcl | 125 | 25 |
| Famotidine | Famotidine | 119 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 119 | 35 |
| Atenolol | Atenolol | 113 | 32 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 113 | 47 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 112 | 14 |
| Eliquis | Apixaban | 107 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 107 | 20 |
| Ibuprofen | Ibuprofen | 106 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 104 | 26 |
| Clonazepam | Clonazepam | 103 | 17 |
| Simvastatin | Simvastatin | 100 | 28 |
| Benazepril Hcl | Benazepril Hcl | 96 | 27 |
| Trazodone Hcl | Trazodone Hcl | 95 | 25 |
| Potassium Chloride | Potassium Chloride | 91 | 26 |
| Fenofibrate | Fenofibrate | 85 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 84 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 82 | 17 |
| Ozempic | Semaglutide | 82 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 81 | 31 |
| Sertraline Hcl | Sertraline Hcl | 80 | 20 |
| Trulicity | Dulaglutide | 77 | 12 |
| Donepezil Hcl | Donepezil Hcl | 75 | 20 |
| Prednisone | Prednisone | 75 | 48 |
| Pravastatin Sodium | Pravastatin Sodium | 67 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 16 |
| Valsartan | Valsartan | 60 | 16 |
| Carvedilol | Carvedilol | 59 | 15 |
| Bupropion Xl | Bupropion Hcl | 58 | 11 |
| Farxiga | Dapagliflozin Propanediol | 58 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 56 | 45 |
| Celecoxib | Celecoxib | 55 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 51 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 51 | suppressed |
| Allopurinol | Allopurinol | 50 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 49 | 13 |
| Montelukast Sodium | Montelukast Sodium | 47 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 47 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 13 |
| Glipizide Er | Glipizide | 45 | 13 |
| Azithromycin | Azithromycin | 44 | 39 |
| Glipizide | Glipizide | 44 | 12 |
| Jardiance | Empagliflozin | 44 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 42 | 33 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | suppressed |
| Irbesartan | Irbesartan | 40 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | 11 |
| Clonidine Hcl | Clonidine Hcl | 39 | 15 |
| Ketoconazole | Ketoconazole | 39 | 17 |
| Synthroid | Levothyroxine Sodium | 39 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 37 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 36 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Finasteride | Finasteride | 35 | 11 |
| Alendronate Sodium | Alendronate Sodium | 34 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Pregabalin | Pregabalin | 33 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 33 | suppressed |
| Estradiol | Estradiol | 32 | suppressed |
| Mirtazapine | Mirtazapine | 32 | suppressed |
| Spironolactone | Spironolactone | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Hydrocortisone | Hydrocortisone | 30 | 11 |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Naproxen | Naproxen | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Rybelsus | Semaglutide | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Diazepam | Diazepam | 29 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 28 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | 11 |
| Megestrol Acetate | Megestrol Acetate | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Cefdinir | Cefdinir | 24 | 22 |
| Linzess | Linaclotide | 24 | suppressed |
| Nystatin | Nystatin | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 23 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Armour Thyroid | Thyroid,pork | 22 | suppressed |
| Indapamide | Indapamide | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 13 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Ciclopirox | Ciclopirox | 19 | suppressed |
| Indomethacin | Indomethacin | 19 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Testosterone | Testosterone | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 16 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Belsomra | Suvorexant | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Lyumjev Kwikpen U-200 | Insulin Lispro-Aabc | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,652.19 · 93 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CREON, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, GLYCATE, JARDIANCE, LEQVIO, LINZESS, LOREEV XR, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, RECORLEV, RELTONE 200 MG, RELTONE 400 MG, REPATHA, Rybelsus, Symbravo, TRELEGY ELLIPTA, Tlando, UBRELVY, VYNDAQEL, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error